Irreversible Nek2 kinase inhibitors with cellular activity

Journal of Medicinal Chemistry

Volumn 54, Issue 12, 2011, Pages 4133-4146

  Henise, Jeffrey C ^a   Taunton, Jack ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(1H IMIDAZOL 5 YL)METHYLENE] 5 (2 CHLOROACETYL)INDOLIN 2 ONE; 3 [(1H PYRROL 2 YL)METHYLENE] 5 (2 CHLOROACETYL)INDOLIN 2 ONE; 3 [(1H PYRROL 2 YL)METHYLENE] 5 (3 OXOBUT 1 ENYL) INDOLIN 2 ONE; 3 [(1H PYRROL 2 YL)METHYLENE] 5 [2 (METHYLSULFONYL) VINYL]INDOLIN 2 ONE; 5 (2 CHLOROACETYL) 3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE] 1 METHYLINDOLIN 2 ONE; 5 (2 CHLOROACETYL) 3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 2 ONE; 5 (2 CHLOROACETYL) 3 [(4 METHYL 1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 2 ONE; 5 ACETYL 3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE]INDOLIN 2 ONE; AURORA B KINASE; CYCLIN DEPENDENT KINASE 1; ETHYL 4 [3 [(1H PYRROL 2 YL)METHYLENE] 2 OXOINDOLIN 5 YLAMINO] 4 OXOBUT 2 ENOATE; JH 295; N [3 [(1H IMIDAZOL 5 YL)METHYLENE] 2 OXOINDOLIN 5 YL]PROPIOLAMIDE; N [3 [(1H PYRROL 2 YL)METHYLENE] 2 OXOINDOLIN 5 YL] 2 CHLOROACETAMIDE; N [3 [(1H PYRROL 2 YL)METHYLENE] 2 OXOINDOLIN 5 YL]ACRYLAMIDE; N [3 [(1H PYRROL 2 YL)METHYLENE] 2 OXOINDOLIN 5 YL]PROPIOLAMIDE; N [3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE] 1 METHYL 2 OXOINDOLIN 5 YL]PROPIOLAMIDE; N [3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE] 2 OXOINDOLIN 5 YL]BUT 2 YNAMIDE; N [3 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYLENE] 2 OXOINDOLIN 5 YL]PROPIOLAMIDE; N [3 [(4 METHYL 1H IMIDAZOL 5 YL)METHYLENE] 2 OXOINDOLIN 5 YL]PROPIOLAMIDE; NEK2 ENZYME; OXINDOLE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; POLO LIKE KINASE 1; SU 11652; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION;

CELL LINE; CHROMOSOMES, HUMAN; HUMANS; INDOLES; MITOTIC SPINDLE APPARATUS; MODELS, MOLECULAR; PROTEIN-SERINE-THREONINE KINASES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79959416870     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200222m     Document Type: Article

References (45)

1. Fry, A. M.; Meraldi, P.; Nigg, E. A. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators EMBO J. 1998, 17, 470-481 (Pubitemid 28045488)
2. ORegan, L.; Blot, J.; Fry, A. M. Mitotic regulation by NIMA-related kinases Cell Div. 2007, 2, 25
3. Bahe, S.; Stierhof, Y. D.; Wilkinson, C. J.; Leiss, F.; Nigg, E. A. Rootletin forms centriole-associated filaments and functions in centrosome cohesion J. Cell Biol. 2005, 171, 27-33 (Pubitemid 41434599)
4. Fry, A. M.; Mayor, T.; Meraldi, P.; Stierhof, Y. D.; Tanaka, K.; Nigg, E. A. C-Nap1, a novel centrosomal coiled-coil protein and candidate substrate of the cell cycle-regulated protein kinase Nek2 J. Cell Biol. 1998, 141, 1563-1574 (Pubitemid 28309171)
5. Mardin, B. R.; Lange, C.; Baxter, J. E.; Hardy, T.; Scholz, S. R.; Fry, A. M.; Schiebel, E. Components of the Hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction Nat. Cell Biol. 2010, 12, 1166-1176
6. Draviam, V. M.; Stegmeier, F.; Nalepa, G.; Sowa, M. E.; Chen, J.; Liang, A.; Hannon, G. J.; Sorger, P. K.; Harper, J. W.; Elledge, S. J. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling Nat. Cell Biol. 2007, 9, 556-564 (Pubitemid 46696537)
7. Kapoor, T. M.; Mayer, T. U.; Coughlin, M. L.; Mitchison, T. J. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5 J. Cell Biol. 2000, 150, 975-988
8. Musacchio, A.; Salmon, E. D. The spindle-assembly checkpoint in space and time Nat. Rev. Mol. Cell Biol. 2007, 8, 379-393 (Pubitemid 46643240)
9. Strebhardt, K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Nat. Rev. Drug Discovery 2010, 9, 643-660
10. Hauf, S.; Cole, R. W.; LaTerra, S.; Zimmer, C.; Schnapp, G.; Walter, R.; Heckel, A.; van Meel, J.; Rieder, C. L.; Peters, J.-M. The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint J. Cell Biol. 2003, 161, 281-294 (Pubitemid 36529847)
11. Tighe, A.; Staples, O.; Taylor, S. Mps1 kinase activity restrains anaphase during an unperturbed mitosis and targets Mad2 to kinetochores J. Cell Biol. 2008, 181, 893-901 (Pubitemid 351846823)
12. Kwiatkowski, N.; Jelluma, N.; Filippakopoulos, P.; Soundararajan, M.; Manak, M. S.; Kwon, M.; Choi, H. G.; Sim, T.; Deveraux, Q. L.; Rottmann, S.; Pellman, D.; Shah, J. V.; Kops, G. J.; Knapp, S.; Gray, N. S. Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function Nat. Chem. Biol. 2010, 6, 359-368
13. Kokuryo, T.; Senga, T.; Yokoyama, Y.; Nagino, M.; Nimura, Y.; Hamaguchi, M. Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma Cancer Res. 2007, 67, 9637-9642 (Pubitemid 47621209)
14. Tsunoda, N.; Kokuryo, T.; Oda, K.; Senga, T.; Yokoyama, Y.; Nagino, M.; Nimura, Y.; Hamaguchi, M. Nek2 as a novel molecular target for the treatment of breast carcinoma Cancer Sci. 2009, 100, 111-116
15. Zeng, X.; Shaikh, F. Y.; Harrison, M. K.; Adon, A. M.; Trimboli, A. J.; Carroll, K. A.; Sharma, N.; Timmers, C.; Chodosh, L. A.; Leone, G.; Saavedra, H. I. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2 Oncogene 2010, 29, 5103-5112
16. Hayward, D. G.; Clarke, R. B.; Faragher, A. J.; Pillai, M. R.; Hagan, I. M.; Fry, A. M. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer Cancer Res. 2004, 64, 7370-7376 (Pubitemid 39372076)
17. Barbagallo, F.; Paronetto, M. P.; Franco, R.; Chieffi, P.; Dolci, S.; Fry, A. M.; Geremia, R.; Sette, C. Increased expression and nuclear localization of the centrosomal kinase Nek2 in human testicular seminomas J. Pathol. 2009, 217, 431-441
18. Andréasson, U.; Dictor, M.; Jerkeman, M.; Berglund, M.; Sundström, C.; Linderoth, J.; Rosenquist, R.; Borrebaeck, C. A.; Ek, S. Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells Am. J. Hematol. 2009, 84, 803-808
19. Whelligan, D. K.; Solanki, S.; Taylor, D.; Thomson, D. W.; Cheung, K. M.; Boxall, K.; Mas-Droux, C.; Barillari, C.; Burns, S.; Grummitt, C. G.; Collins, I.; van Montfort, R. L.; Aherne, G. W.; Bayliss, R.; Hoelder, S. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization J. Med. Chem. 2010, 53, 7682-7698
20. Emmitte, K. A.; Adjabeng, G. M.; Andrews, C. W.; Alberti, J. G.; Bambal, R.; Chamberlain, S. D.; Davis-Ward, R. G.; Dickson, H. D.; Hassler, D. F.; Hornberger, K. R.; Jackson, J. R.; Kuntz, K. W.; Lansing, T. J.; Mook, R. A., Jr.; Nailor, K. E.; Pobanz, M. A.; Smith, S. C.; Sung, C. M.; Cheung, M. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding Bioorg. Med. Chem. Lett. 2009, 19, 1694-1697
21. Hayward, D. G.; Newbatt, Y.; Pickard, L.; Byrne, E.; Mao, G.; Burns, S.; Sahota, N. K.; Workman, P.; Collins, I.; Aherne, W.; Fry, A. M. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated Nek2 kinase J. Biomol. Screening 2010, 15, 918-927
22. Rellos, P.; Ivins, F. J.; Baxter, J. E.; Pike, A.; Nott, T. J.; Parkinson, D.-M.; Das, S.; Howell, S.; Fedorov, O.; Shen, Q. Y.; Fry, A. M.; Knapp, S.; Smerdon, S. J. Structure and regulation of the human Nek2 centrosomal kinase J. Biol. Chem. 2006, 282, 6833-6842
23. Singh, J.; Dobrusin, E. M.; Fry, D. W.; Haske, T.; Whitty, A.; McNamara, D. J. Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the ErbB receptor subfamily of protein tyrosine kinases J. Med. Chem. 1997, 40, 1130-1135 (Pubitemid 27149266)
24. Singh, J.; Petter, R. C.; Kluge, A. F. Targeted covalent drugs of the kinase family Curr. Opin. Chem. Biol. 2010, 14, 475-480
25. Zhou, W.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Jänne, P. A. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Nature 2009, 462, 1070-1074
26. Leproult, E.; Barluenga, S.; Moras, D.; Wurtz, J. M.; Winssinger, N. Cysteine mapping in conformationally distinct kinase nucleotide binding sites: application to the design of selective covalent inhibitors J. Med. Chem. 2011, 54, 1347-1355
27. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 2009, 9, 28-39
28. Honigberg, L. A.; Smith, A. M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D. H.; Miller, R. A.; Buggy, J. J. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 13075-13080
29. Cohen, M. S.; Zhang, C.; Shokat, K. M.; Taunton, J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 2005, 308, 1318-1321 (Pubitemid 40746129)
30. Cohen, M. S.; Hadjivassiliou, H.; Taunton, J. A clickable inhibitor reveals context-dependent autoactivation of p90 RSK Nat. Chem. Biol. 2007, 3, 156-160
31. Zhou, W.; Hur, W.; McDermott, U.; Dutt, A.; Xian, W.; Ficarro, S. B.; Zhang, J.; Sharma, S. V.; Brugge, J.; Meyerson, M.; Settleman, J.; Gray, N. S. A structure-guided approach to creating covalent FGFR inhibitors Chem. Biol. 2010, 17, 285-295
32. Doehn, U.; Hauge, C.; Frank, S. R.; Jensen, C. J.; Duda, K.; Nielsen, J. V.; Cohen, M. S.; Johansen, J. V.; Winther, B. R.; Lund, L. R.; Winther, O.; Taunton, J.; Hansen, S. H.; Frödin, M. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells Mol. Cell 2009, 35, 511-22
33. Moshinsky, D. J.; Bellamacina, C. R.; Boisvert, D. C.; Huang, P.; Hui, T.; Jancarik, J.; Kim, S. H.; Rice, A. G. SU9516: biochemical analysis of Cdk inhibition and crystal structure in complex with Cdk2 Biochem. Biophys. Res. Commun. 2003, 310, 1026-1031 (Pubitemid 37188725)
34. Vassilev, L. T.; Tovar, C.; Chen, S.; Knezevic, D.; Zhao, X.; Sun, H.; Heimbrook, D. C.; Chen, L. Selective small-molecule inhibitor reveals critical mitotic functions of human Cdk1 Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 10660-10665 (Pubitemid 44078033)
35. Potapova, T. A.; Daum, J. R.; Pittman, B.D.; Hudson, J. R.; Jones, T. N.; Satinover, D. L.; Stukenberg, P. T.; Gorbsky, G. J. The reversibility of mitotic exit in vertebrate cells Nature 2006, 440, 954-958
36. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J. M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336 (Pubitemid 41094421)
37. Fu, G.; Ding, X.; Yuan, K.; Aikhionbare, F.; Yao, J.; Cai, X.; Jiang, K.; Yao, X. Phosphorylation of human Sgo1 by NEK2A is essential for chromosome congression in mitosis Cell Res. 2007, 17, 608-618 (Pubitemid 47116356)
38. Faragher, A. J.; Fry, A. M. Nek2A kinase stimulates centrosome disjunction and is required for formation of bipolar mitotic spindles Mol. Biol. Cell 2003, 14, 2876-2889 (Pubitemid 36871528)
39. Peters, U.; Cherian, J.; Kim, J. H.; Kwok, B. H.; Kapoor, T. M. Probing cell-division phenotype space and Polo-like kinase function using small molecules Nat. Chem. Biol. 2006, 2, 618-626 (Pubitemid 44610346)
40. McInnes, C.; Mazumdar, A.; Mezna, M.; Meades, C.; Midgley, C.; Scaerou, F.; Carpenter, L.; Mackenzie, M.; Taylor, P.; Walkinshaw, M.; Fischer, P. M.; Glover, D. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance Nat. Chem. Biol. 2006, 2, 608-617 (Pubitemid 44610345)
41. Lénárt, P.; Petronczki, M.; Steegmaier, M.; Di Fiore, B.; Lipp, J. J.; Hoffmann, M.; Rettig, W. J.; Kraut, N.; Peters, J. M. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1 Curr. Biol. 2007, 17, 304-315
42. Tang, P. C.; Sun, Li.; Mcmahon, G.; Blake, R. A. 3-(Cyclohexano- heteroarylidenyl)-2-indolinone Protein Tyrosine Kinase Inhibitors. U.S. Patent 6114371, 2000.
43. Mintz, M. J.; Walling, C. t -Butyl Hypochlorite. Organic Syntheses; Wiley & Sons: New York, 1969; Collect. Vol. 49, p 9.
44. Dallinger, D.; Kappe, C. O. Rapid preparation of the mitotic kinesin Eg5 inhibitor monastrol using controlled microwave-assisted synthesis Nat. Protoc. 2007, 2, 317-321 (Pubitemid 47040045)
45. Chen, S.; Chen, L.; Le, N. T.; Zhao, C.; Sidduri, A.; Lou, J. P.; Michoud, C.; Portland, L.; Jackson, N.; Liu, J. J.; Konzelmann, F.; Chi, F.; Tovar, C.; Xiang, Q.; Chen, Y.; Wen, Y.; Vassilev, L. T. Synthesis and activity of quinolinyl-methylene-thiazolinones as potent and selective cyclin-dependent kinase 1 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 2134-2138 (Pubitemid 46484313)